5V7 Stock Overview
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
VentriPoint Diagnostics Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.13 |
52 Week High | CA$0.24 |
52 Week Low | CA$0.073 |
Beta | 0.40 |
1 Month Change | -9.52% |
3 Month Change | -31.79% |
1 Year Change | 46.96% |
3 Year Change | -64.44% |
5 Year Change | 129.31% |
Change since IPO | -30.00% |
Recent News & Updates
Recent updates
Shareholder Returns
5V7 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | -5.7% | 1.7% | 1.7% |
1Y | 47.0% | -7.7% | 2.3% |
Return vs Industry: 5V7 exceeded the German Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: 5V7 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
5V7 volatility | |
---|---|
5V7 Average Weekly Movement | 12.0% |
Medical Equipment Industry Average Movement | 4.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5V7's share price has been volatile over the past 3 months.
Volatility Over Time: 5V7's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | n/a | Hugh MacNaught | www.ventripoint.com |
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity of chemotherapy treatments for cancer, and Covid-19 related heart issues.
VentriPoint Diagnostics Ltd. Fundamentals Summary
5V7 fundamental statistics | |
---|---|
Market cap | €23.58m |
Earnings (TTM) | -€3.23m |
Revenue (TTM) | €24.48k |
919.8x
P/S Ratio-7.0x
P/E RatioIs 5V7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
5V7 income statement (TTM) | |
---|---|
Revenue | CA$35.89k |
Cost of Revenue | CA$12.61k |
Gross Profit | CA$23.28k |
Other Expenses | CA$4.76m |
Earnings | -CA$4.74m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.03 |
Gross Margin | 64.86% |
Net Profit Margin | -13,205.39% |
Debt/Equity Ratio | 10.8% |
How did 5V7 perform over the long term?
See historical performance and comparison